Tech Company Financing Transactions
Baseimmune Funding Round
On 2/26/2024, Baseimmune announced $11.3 million in Series A financing from IQ Capital Fund, MSD Partners and Creator Fund.
Transaction Overview
Company Name
Announced On
2/26/2024
Transaction Type
Venture Equity
Amount
$11,300,000
Round
Series A
Investors
IQ Capital Fund (Lead Investor) (Alex Wilson)
MSD Partners (Lead Investor) (David Rubin)
Proceeds Purpose
This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
London BioScience Innovation Centre, 2 Royal College Street
London, NW1 0NH
UK
London, NW1 0NH
UK
Phone
Undisclosed
Website
Email Address
Overview
We combine scientific expertise with our proprietary AI-platform to generate mutation-resistant vaccines. Modelling pathogen evolution and immune response to generate vaccines against emerging and complex pathogens that have been failed by traditional approaches.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Blight
Chief Scientific Officer
Ariane Gomes
Chief Technical Officer
Phillip Kemlo
Browse more venture capital transactions:
Prev: 2/26/2024: Altilium Clean Technology venture capital transaction
Next: 2/26/2024: Rototip venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs